AZN - Biotech News Recap: Upcoming Presentations For Krystal Biotech At SID
Krystal Biotech (KRYS) - The company announced presentations of clinical data for KB103 to treat DEB (dystrophic epidermolysis bullosa) and preclinical data on KB105 for the treatment of autosomal recessive congenital ichthyosis (ARCI) and KB104 for the treatment of Netherton syndrome at the Society for Investigative Dermatology Annual Meeting on May 9th. However, readers should be aware that the first presentation for KB103 will share data that was already disclosed from the ongoing GEM-1 phase 1/2 study. Preclinical data for KB105 in ARCI will be of interest as well, considering that IND filing is expected